Lyell Immunopharma, Inc. (LYEL) vs Entrada Therapeutics, Inc. (TRDA)
A side-by-side comparison of Lyell Immunopharma, Inc. and Entrada Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LYEL
Lyell Immunopharma, Inc.
$8.72HealthcareDelayed quote: Oct 6, 2026, 3:50 PM EDT
TRDA
Entrada Therapeutics, Inc.
$5.40HealthcareDelayed quote: Oct 6, 2026, 3:50 PM EDT
Total return — LYEL vs TRDA
growth of $100 · dividends reinvested · last 5yLYEL -96.7% (-49.6%/yr)TRDA -77.1% (-25.5%/yr)TRDA compounded faster over this window
Log scale — wide-divergence pair
LYEL TRDA
LYEL vs TRDA: by the numbers
- •LYEL is the larger company ($214M vs $209M market cap).
- •Both run net losses; TRDA's is the smaller (-3537.73% vs -920285.19% net margin).
Metrics side by side
Valuation
| Metric | LYEL | TRDA |
|---|---|---|
| P/S ratio | 7910.01 | 44.69 |
| P/B ratio | 0.91 | 0.90 |
Profitability
| Metric | LYEL | TRDA |
|---|---|---|
| Gross margin | -31952.78% | 83.89% |
| Operating margin | -566038.89% | -613.66% |
| Net margin | -920285.19% | -3537.73% |
| ROE | -106.27% | -71.02% |
| ROIC | -70.80% | -63.61% |
Growth (annualized)
| Metric | LYEL | TRDA |
|---|---|---|
| Revenue CAGR (5Y) | -68.32% | N/A |
| Total return CAGR (5Y) | -48.18% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.